Myeloma natural killer cells are exhausted and have impaired regulation of activation

Criselle D'Souza; Simon P Keam; Han Xian Aw Yeang; Michael Neeson; Kelden Richardson; Andy K Hsu; Rachael Canfield; Natalie Bezman; Michael Robbins; Hang Quach; David S Ritchie; Simon J Harrison; Joseph A Trapani; H Miles Prince; Paul A Beavis; Phillip K Darcy; Paul J Neeson

doi:10.3324/haematol.2020.277525

Myeloma natural killer cells are exhausted and have impaired regulation of activation

Haematologica. 2021 Sep 1;106(9):2522-2526. doi: 10.3324/haematol.2020.277525.

Authors

Criselle D'Souza¹, Simon P Keam², Han Xian Aw Yeang³, Michael Neeson³, Kelden Richardson³, Andy K Hsu³, Rachael Canfield³, Natalie Bezman⁴, Michael Robbins⁵, Hang Quach⁶, David S Ritchie⁷, Simon J Harrison⁸, Joseph A Trapani⁹, H Miles Prince¹⁰, Paul A Beavis⁹, Phillip K Darcy⁹, Paul J Neeson¹¹

Affiliations

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne. criselle.dsouza@petermac.org.
² Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne.
³ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne.
⁴ Oncology Discovery Research, Bristol-Myers Squibb, Redwood City, CA, USA. Current: Arsenal Bio, San Francisco, CA 94080.
⁵ Translational Medicine, Bristol-Myers Squibb, Cambridge, MA, USA, (current: io904 LLC).
⁶ Department of Hematology, St Vincent's Hospital, Melbourne, Australia; Faculty of Medicine, University of Melbourne.
⁷ Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Faculty of Medicine, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
⁸ Tumour Suppression and Cancer Sex Disparity Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
⁹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne.
¹⁰ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Clinical Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne.
¹¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne. paul.neeson@petermac.org.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cytotoxicity, Immunologic
Flow Cytometry
Humans
Killer Cells, Natural
Multiple Myeloma*

Grants and funding

Funding: funding for this study was provided by Cure Cancer Australia, Australian NHMRC program grant No. 113 2373 and Bristol-Myers Squibb.